Compare BioNTech SE - ADR (BNTX) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Snap On Incorporated — how do they compare? BioNTech SE - ADR trades at $93.34 (market cap $23.31B), while Snap On Incorporated trades at $409.72 (market cap $21.30B). The key difference: BioNTech SE - ADR and Snap On Incorporated are close in size by market cap, and Snap On Incorporated pays a 2.37% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | SNA | |
|---|---|---|
Market Cap | $23.31B | $21.30B |
Sector | Health | Technology |
52-Week High | $119.34 | $419.31 |
52-Week Low | $83.89 | $321.38 |
Enterprise Value | $6.60B | $20.93B |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Snap-on Incorporated (SNA) trades at $407.78, down 0.81% on the day, with a bullish technical outlook supported by moving averages. The company maintains strong fundamentals with 19.6% net income margin and 17.58% ROE, though valuation metrics appear elevated at P/E 21.01 and P/S 4.12. Recent Q2 2026 earnings beat expectations with $4.96 EPS, while the $100 million Diesel Laptops acquisition expands diagnostic capabilities.
SNA offers growth potential through strategic acquisitions and operational efficiency, with analyst consensus target of $455.33 suggesting 11.7% upside. Key risks include integration challenges from recent acquisitions and premium valuation pressure. The bullish technical setup combined with strong profitability supports a positive medium-term outlook despite near-term valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
